Market Cap 28.72M
Revenue (ttm) 0.00
Net Income (ttm) -16.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,218,600
Avg Vol 38,164,934
Day's Range N/A - N/A
Shares Out 60.07M
Stochastic %K 23%
Beta 3.43
Analysts Strong Sell
Price Target $3.25

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7381
Fax: 203 557 3023
Address:
1 Enterprise Drive, Suite 430, Shelton, United States
Obax
Obax Nov. 15 at 6:17 AM
1 · Reply
Obax
Obax Nov. 15 at 6:13 AM
0 · Reply
Obax
Obax Nov. 15 at 6:11 AM
0 · Reply
Badnanny
Badnanny Nov. 15 at 5:53 AM
$INTS Chat gpts take is positive, that's enuf for me.
0 · Reply
IggyKoopa
IggyKoopa Nov. 14 at 11:07 PM
$INTS if they are filling any extension for 12/3/25 compliance deadline, they should be filing doc soon. To make sure approval, company should file at least 5–10 business days in advance (by November 21–26, 2025), allowing time for Nasdaq review and any follow-up. You will know soon enough. Have a safe weekend🌈
3 · Reply
Bearfaith
Bearfaith Nov. 14 at 10:43 PM
$INTS the stock price didn’t move much with this low volume of 2M this means something is brewing
0 · Reply
jverde
jverde Nov. 14 at 10:02 PM
$INTS looks like not reverse split news today?
1 · Reply
Atrain1189
Atrain1189 Nov. 14 at 9:15 PM
$INTS seems like a mixture of impatient retail and more shorting going on. When it’s low volume this gets clobbered but when it moves it can run crazy. Definitely worth the risk at these levels! 10-20x stock in the next 18 months with some favorable news
1 · Reply
Bearfaith
Bearfaith Nov. 14 at 9:13 PM
$INTS we are down to only 2 million in volume. Dang
0 · Reply
alcat1973
alcat1973 Nov. 14 at 9:04 PM
$INTS Crickets!
0 · Reply
Latest News on INTS
Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 11:46 PM EDT - 5 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering


Obax
Obax Nov. 15 at 6:17 AM
1 · Reply
Obax
Obax Nov. 15 at 6:13 AM
0 · Reply
Obax
Obax Nov. 15 at 6:11 AM
0 · Reply
Badnanny
Badnanny Nov. 15 at 5:53 AM
$INTS Chat gpts take is positive, that's enuf for me.
0 · Reply
IggyKoopa
IggyKoopa Nov. 14 at 11:07 PM
$INTS if they are filling any extension for 12/3/25 compliance deadline, they should be filing doc soon. To make sure approval, company should file at least 5–10 business days in advance (by November 21–26, 2025), allowing time for Nasdaq review and any follow-up. You will know soon enough. Have a safe weekend🌈
3 · Reply
Bearfaith
Bearfaith Nov. 14 at 10:43 PM
$INTS the stock price didn’t move much with this low volume of 2M this means something is brewing
0 · Reply
jverde
jverde Nov. 14 at 10:02 PM
$INTS looks like not reverse split news today?
1 · Reply
Atrain1189
Atrain1189 Nov. 14 at 9:15 PM
$INTS seems like a mixture of impatient retail and more shorting going on. When it’s low volume this gets clobbered but when it moves it can run crazy. Definitely worth the risk at these levels! 10-20x stock in the next 18 months with some favorable news
1 · Reply
Bearfaith
Bearfaith Nov. 14 at 9:13 PM
$INTS we are down to only 2 million in volume. Dang
0 · Reply
alcat1973
alcat1973 Nov. 14 at 9:04 PM
$INTS Crickets!
0 · Reply
Hekinsieden
Hekinsieden Nov. 14 at 8:56 PM
0 · Reply
Bearfaith
Bearfaith Nov. 14 at 8:28 PM
$INTS This board is as quiet as WBD…
0 · Reply
Debi_G
Debi_G Nov. 14 at 7:31 PM
$INTS — If the stock doesn’t rebound or get a boost from meaningful Phase 3 news, a squeeze, or a reverse split by late November, the company will likely file an appeal for a 180-day extension by early December. That would buy time but also signal weakness compared to the quicker fix of a split. However, if INT230-6 delivers strong Phase 3 results, the stock’s upside could be significant.
1 · Reply
Doubletel
Doubletel Nov. 14 at 7:24 PM
$INTS $CDTX Report : Merck to acquire Cidara Therapeutics for $9.2 billion $INTS next
0 · Reply
Swerbian
Swerbian Nov. 14 at 6:40 PM
$INTS would love a press release of some sort today
1 · Reply
alby777
alby777 Nov. 14 at 6:29 PM
$INTS CDTX Cidara Therapeutics Inc Trending $218.10 Today up +$112.11 (+105.77%) Today INTS is next?
0 · Reply
alby777
alby777 Nov. 14 at 5:24 PM
$INTS Significant Undervaluation Relative to Price Targets: Even after recent downward revisions, the average one-year price target for INTS is $6.22, with a high of $15.75 and a low of $3.03.2 This indicates that analysts believe the current stock price is dramatically below its intrinsic value or future potential, offering substantial upside if their projections materialize...
0 · Reply
alby777
alby777 Nov. 14 at 5:22 PM
$INTS https://fintel.io/topic/how-do-analysts-justify-buy-ratings-for-ints-given-the-9405-stock-price-decline-since-august-2024-1938-4329
0 · Reply
alby777
alby777 Nov. 14 at 5:09 PM
$INTS M&A? MERCK?
2 · Reply
alby777
alby777 Nov. 14 at 5:07 PM
$INTS Additionally, Sentinus, LLC, Jane Street Group, LLC, Virtu Financial LLC, and Boothbay Fund Management LLC were among the institutions that reported increasing their holdings in the second quarter of 2025
0 · Reply
alby777
alby777 Nov. 14 at 5:05 PM
$INTS Based on filings as of September 30, 2025, notable purchasers include: Geode Capital Management, LLC: Increased its holdings by 255.56%, adding 186,078 shares. Vanguard Group Inc.: Increased its stake by 530.58%, adding 215,346 shares. Mesirow Financial Investment Management, Inc.: Increased its position by 81.82%, acquiring 90,000 additional shares. Stonebridge Financial Group, LLC: Grew its holdings by 229.06%, purchasing 37,852 more shares. Citigroup Inc.: Acquired 44,575 shares. Sigma Planning Corp: Held 69,167 shares. Blair William & Co. (IL): Held 37,805 shares. One Charles Private Wealth Management: Held 31,800 shares. EWA, LLC: Grew its holdings by 19.87%, adding 3,186 shares
0 · Reply
alby777
alby777 Nov. 14 at 5:01 PM
$INTS INTS EPS is forecasted to grow by 77.27% YoY from Q4 2024 to Q4 2025 INTS EPS YoY is forecasted to grow 77.27% which is 70.52% above its peer average
0 · Reply